Dinner S, Dunn TJ, Price E, et al. A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide, weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. Int J Hematol. 2018, 108(3):267-273. doi: 10.1007/s12185-018-2468-5.
Advertisement
Articles by Dinner S, Dunn TJ, Price E, et al. A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide, weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. Int J Hematol. 2018, 108(3):267-273. doi: 10.1007/s12185-018-2468-5.
Advertisement
Latest Updated Articles
- Study Summary: Amrubicin, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Published: October 24th 2018 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Virtual Reality Intervention Increased Empathy for Patients With MG
2
Strong Patient–Doctor Communication Improves Glaucoma Care: Ariana Levin, MD
3
Most Patients With MCL in Study of Pirtobrutinib Show Stable or Improved Physical Symptoms, QOL
4
Mental Health Distress in Nonmelanoma Skin Cancer Largely Driven by Sociodemographic, Comorbid Factors
5
